Vanguard Group
OCAT

Vanguard Group’s OCATA THERAPEUTICS, INC. COMMON STOCK OCAT Stock Holding History

Vanguard Group’s Portfolio OCAT Stock Details OCAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-1,262,009
Closed -$10.6M – 4183
2015
Q4 		$10.6M Buy
1,262,009
+189,033
+18% +$1.27M ﹤0.01% 2601
2015
Q3 		$4.49M Buy
1,072,976
+289,426
+37% +$1.26M ﹤0.01% 3017
2015
Q2 		$4.13M Buy
783,550
+769,250
+5,379% +$4.93M ﹤0.01% 3101
2015
Q1 		$88K Buy
+14,300
New +$91.6K ﹤0.01% 4087

Vanguard Group's OCAT Position: Q1 2016 in Review

Vanguard Group sold out of OCATA THERAPEUTICS, INC. COMMON STOCK (OCAT) in Q1 2016, closing a stake of 1,262,009 shares — an estimated $10.6M sold.

Vanguard Group first reported a position in OCAT in Q1 2015 and held it in 4 quarters. The position peaked at $10.6M in Q4 2015. 1 fund tracked by Wall St. Rank holds OCAT as of Q1 2016.

  • Vanguard Group reported no remaining OCATA THERAPEUTICS, INC. COMMON STOCK position as of Q1 2016 after selling out during the quarter.
  • Vanguard Group sold 1,262,009 OCATA THERAPEUTICS, INC. COMMON STOCK shares in Q1 2016, an estimated $10.6M.
  • Vanguard Group first reported a position in OCATA THERAPEUTICS, INC. COMMON STOCK in Q1 2015 and held it in 4 quarters.
  • Vanguard Group's OCATA THERAPEUTICS, INC. COMMON STOCK position peaked at $10.6M in Q4 2015.
  • 1 fund tracked by Wall St. Rank held OCATA THERAPEUTICS, INC. COMMON STOCK as of Q1 2016.

Based on Vanguard Group's 13F filing for Q1 2016, filed 13 May 2016.